Search results for "Hazard"

showing 10 items of 1517 documents

An investigation of the diagnostic, predictive, and prognostic impacts of three colonic biopsy grading systems for acute graft versus host disease.

2021

Acute graft versus host disease (aGvHD) is an important, life-threatening complication after allogeneic hematopoietic stem cell transplantation (alloHSCT). To investigate the value of multiple simultaneous colon biopsies in improving diagnostic accuracy in patients with aGvHD, we retrospectively analyzed 157 patients after alloHSCT. The biopsies were evaluated individually using three established histological grading systems (Lerner, Sale, and Melson). The maximum, minimum, median, and mean histological aGvHD grades were calculated for each patient, and the results were correlated with the Glucksberg grade of clinical manifestation of GvHD, steroid therapy status, and outcome. We found that…

MaleMultivariate analysismedicine.medical_treatmentBiopsyGraft vs Host DiseaseApoptosisHematopoietic stem cell transplantationGastroenterologySteroid TherapyMedicine and Health SciencesMedicineStage (cooking)Multidisciplinarymedicine.diagnostic_testCell DeathPharmaceuticsOrganic CompoundsQRMiddle AgedPrognosisChemistryTreatment OutcomeCell ProcessesAcute DiseasePhysical SciencesMedicineFemaleSteroidsAnatomyResearch ArticleAdultmedicine.medical_specialtyHistologyAdolescentColonScienceSurgical and Invasive Medical ProceduresYoung AdultDrug TherapyInternal medicineBiopsyHumansddc:610Grading (tumors)AgedProportional Hazards Modelsbusiness.industryOrganic ChemistryChemical CompoundsBiology and Life SciencesHistologyEndoscopyCell BiologyEndoscopyGastrointestinal TractMultivariate AnalysisComplicationbusinessDigestive SystemPloS one
researchProduct

Pimonidazole labelling and response to fractionated irradiation of five human squamous cell carcinoma (hSCC) lines in nude mice: The need for a multi…

2006

To investigate the influence on local control after fractionated radiotherapy of hypoxia measured in unirradiated tumours using the hypoxic marker Pimonidazole, using multivariate approaches.Five human squamous cell carcinoma lines (FaDu, UT-SCC-15, UT-SCC-14, XF354, and UT-SCC-5) were transplanted subcutaneously into the right hind-leg of NMRI nude mice. Histological material was collected from 60 unirradiated tumours after injection of Pimonidazole. The relative hypoxic area within the viable tumour area (Pimonidazole hypoxic fraction, pHF) was determined in seven serial 10 microm cross-sections per tumour by fluorescence microscopy and computerized image analysis. Local tumour control wa…

MaleMultivariate statisticsPathologymedicine.medical_specialtyMice NudeMiceImaging Three-DimensionalCell Line TumorLabellingBiomarkers TumorCarcinomamedicineAnimalsHumansPimonidazoleRadiology Nuclear Medicine and imagingProportional hazards modelbusiness.industryDose fractionationHematologyHypoxia (medical)Prognosismedicine.diseaseXenograft Model Antitumor AssaysCell HypoxiaTreatment OutcomeOncologyNitroimidazolesCarcinoma Squamous CellBiomarker (medicine)FemaleDose Fractionation Radiationmedicine.symptombusinessRadiotherapy and Oncology
researchProduct

Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome

2015

BACKGROUND: Cardiovascular morbidity and mortality are higher among patients with type 2 diabetes, particularly those with concomitant cardiovascular diseases, than in most other populations. We assessed the effects of lixisenatide, a glucagon-like peptide 1-receptor agonist, on cardiovascular outcomes in patients with type 2 diabetes who had had a recent acute coronary event.METHODS: We randomly assigned patients with type 2 diabetes who had had a myocardial infarction or who had been hospitalized for unstable angina within the previous 180 days to receive lixisenatide or placebo in addition to locally determined standards of care. The trial was designed with adequate statistical power to …

MaleMyocardial InfarctionKaplan-Meier Estimate2700 General MedicineType 2 diabetesAnginachemistry.chemical_compoundTreatment FailureMyocardial infarctionResearch Support Non-U.S. Gov'tHemoglobin AGeneral MedicineAnginaMiddle AgedMulticenter StudyCardiovascular DiseasesRandomized Controlled TrialCardiologyFemalelixisenatideType 2medicine.medical_specialtyAcute coronary syndromeGlycosylated610 Medicine & healthUnstableGlucagon-Like Peptide-1 Receptor11171 Cardiocentro TicinoLixisenatideAcute Coronary Syndrome; Aged; Angina Unstable; Cardiovascular Diseases; Diabetes Mellitus Type 2; Female; Glucagon-Like Peptide-1 Receptor; Hemoglobin A Glycosylated; Humans; Hypoglycemic Agents; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Peptides; Proportional Hazards Models; Treatment FailureInternal medicineJournal ArticleDiabetes MellitusmedicineHumansHypoglycemic AgentsAngina UnstableAcute Coronary SyndromeAgedProportional Hazards ModelsHemoglobin A GlycosylatedUnstable anginabusiness.industrySemaglutideta3121medicine.diseaseDiabetes Mellitus Type 2chemistryMyocardial infarction complicationsPeptidesbusinessNew England Journal of Medicine
researchProduct

Predictive value for cardiovascular events of common carotid intima media thickness and its rate of change in individuals at high cardiovascular risk…

2018

AIMS: Carotid intima media thickness (CIMT) predicts cardiovascular (CVD) events, but the predictive value of CIMT change is debated. We assessed the relation between CIMT change and events in individuals at high cardiovascular risk. METHODS AND RESULTS: From 31 cohorts with two CIMT scans (total n = 89070) on average 3.6 years apart and clinical follow-up, subcohorts were drawn: (A) individuals with at least 3 cardiovascular risk factors without previous CVD events, (B) individuals with carotid plaques without previous CVD events, and (C) individuals with previous CVD events. Cox regression models were fit to estimate the hazard ratio (HR) of the combined endpoint (myocardial infarction, s…

MaleMyocardial Infarctionlcsh:MedicinePROGRESSIONCardiovascular Medicine030204 cardiovascular system & hematologyVascular MedicineBiochemistryCarotid Intima-Media ThicknessGeographical locationsDISEASE0302 clinical medicineRisk FactorsGermanyMedicine and Health SciencesMedicineCardiac and Cardiovascular SystemsMyocardial infarctionskin and connective tissue diseaseslcsh:ScienceARTERY INTIMAStrokeIntersectoral CollaborationPOPULATIONCardiovascular Diseases/diagnosisMETABOLIC SYNDROMEeducation.field_of_studyKardiologiMultidisciplinaryAgricultural and Biological Sciences(all)VDP::Medical disciplines: 700::Clinical medical disciplines: 750QHazard ratioVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750RMiddle AgedPrognosisPredictive value3. Good healthStrokeEuropeNeurologyItalyCardiovascular DiseasesHYPERTENSIVE MENCardiologycardiovascular systemMedicineFemaleResearch Articlemedicine.medical_specialtyHigh cardiovascular risk.Cerebrovascular DiseasesSciencePopulationCardiology030209 endocrinology & metabolismATHEROSCLEROSIS RISKArbetsmedicin och miljömedicin03 medical and health sciencesCarotid intima media thickness (CIMT)Internal medicineHumansEuropean Unionddc:610cardiovascular diseaseseducationAgedSwedenBiochemistry Genetics and Molecular Biology(all)Proportional hazards modelbusiness.industrylcsh:RHealth Risk AnalysisCorrectionOccupational Health and Environmental HealthAtherosclerosismedicine.diseaseConfidence intervalHealth CareIntima-media thicknessMYOCARDIAL-INFARCTIONMedical Biophysicslcsh:QVASCULAR RISKsense organsCarotid intima media thickness Cardiovascular riskPeople and placesMetabolic syndromebusinessFOLLOW-UP030217 neurology & neurosurgeryGenetics and Molecular Biology(all)
researchProduct

Myelodysplastic syndromes with 20q deletion: incidence, prognostic value and impact on response to azacitidine of ASXL1 chromosomal deletion and gene…

2021

In myelodysplastic syndromes (MDS), the 20q deletion [del(20q)] may cause deletion of the ASXL1 gene. We studied 153 patients with MDS and del(20q) to assess the incidence, prognostic value and impact on response to azacitidine (AZA) of ASXL1 chromosomal alterations and genetic mutations. Additionally, in vitro assay of the response to AZA in HAP1 (HAP1(WT)) and HAP1 ASXL1 knockout (HAP1(KN)) cells was performed. ASXL1 chromosomal alterations were detected in 44 patients (28 center dot 5%): 34 patients (22%) with a gene deletion (ASXL1(DEL)) and 10 patients (6 center dot 5%) with additional gene copies. ASXL1(DEL) was associated with a lower platelet count. The most frequently mutated genes…

MaleOncologyAntimetabolites Antineoplasticazacitidinemedicine.medical_specialtyAzacitidineASXL1Gene mutationInternal medicinemedicineHumansGeneChromosomal DeletionAged20q deletiongene mutationsAged 80 and overbusiness.industryIncidenceMyelodysplastic syndromesIncidence (epidemiology)Hazard ratioHematologyMiddle AgedPrognosismedicine.diseasemyelodysplastic syndromesConfidence intervalRepressor ProteinsMyelodysplastic SyndromesMutationAzacitidineFemaleChromosome Deletionbusinessmedicine.drugBritish Journal of Haematology
researchProduct

Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma

2015

Objective: This is the final report of a phase III randomized study to evaluate whole-brain radiotherapy (WBRT) in primary therapy of primary CNS lymphoma (PCNSL) after a median follow-up of 81.2 months. Methods: Patients with newly diagnosed PCNSL were randomized to high-dose methotrexate (HDMTX)–based chemotherapy alone or followed by WBRT. We hypothesized that the omission of WBRT would not compromise overall survival (OS; primary endpoint), using a noninferiority design with a margin of 0.9. Results: In the per-protocol population (n = 320), WBRT nonsignificantly prolonged progression-free survival (PFS) (median 18.2 vs 11.9 months, hazard ratio [HR] 0.83 [95% confidence interval (CI) 0…

MaleOncologyAntimetabolites Antineoplasticmedicine.medical_specialtyLymphomamedicine.medical_treatmentPopulationMedizin610 Medicine & healthDisease-Free Survivallaw.inventionCentral Nervous System NeoplasmsRandomized controlled triallawInternal medicinemedicineClinical endpointHumanseducationAgededucation.field_of_studyChemotherapybusiness.industryHazard ratioAntineoplastic ProtocolsMiddle AgedCombined Modality TherapyConfidence interval10040 Clinic for NeurologyRadiation therapyMethotrexateTreatment Outcome2728 Neurology (clinical)MethotrexateNeurology (clinical)Cranial Irradiationbusinessmedicine.drug
researchProduct

Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study

2001

Researchers worldwide with information about the Kirsten ras (Ki-ras) tumour genotype and outcome of patients with colorectal cancer were invited to provide that data in a schematized format for inclusion in a collaborative database called RASCAL (The Kirsten ras in-colorectal-cancer collaborative group). Our results from 2721 such patients have been presented previously and for the first time in any common cancer, showed conclusively that different gene mutations have different impacts on outcome, even when the mutations occur at the same site on the genome. To explore the effect of Ki-ras mutations at different stages of colorectal cancer, more patients were recruited to the database, whi…

MaleOncologyCancer ResearchPathologyMultivariate analysisDatabases FactualSettore MED/06 - Oncologia MedicaColorectal cancerGene mutationmedicine.disease_cause0302 clinical medicineGenotypeColorectal cancer Ki-ras mutationRegistriesAged 80 and over0303 health sciencesMutationValineMiddle Aged3. Good healthKRAS Mutation Analysismedicine.anatomical_structureOncologyPresented by the Kirsten ras in-colorectal-cancer collaborative group030220 oncology & carcinogenesisFemaleColorectal NeoplasmsAdultmedicine.medical_specialtyAdolescentGenotypeoverall survivalMutation MissenseRectumcolorectal cancerDisease-Free Survival03 medical and health sciencesInternal medicinemedicineHumansPoint MutationK-rasCodoncolorectal cancer; K-ras; prognosis; overall survivalAgedNeoplasm StagingProportional Hazards Models030304 developmental biologybusiness.industryCancermedicine.diseaseSurvival AnalysisGenes rasMultivariate Analysisprognosisbusiness
researchProduct

The prognostic value of biological markers in paediatric Hodgkin lymphoma

2015

Abstract Background Many biological and inflammatory markers have been proposed as having a prognostic value at diagnosis of Hodgkin lymphoma (HL), but very few have been validated in paediatric patients. We explored the significance of these markers in a large population of 769 affected children. Patients and methods By using the database of patients enrolled in A.I.E.O.P. (Associazione Italiana di Emato-Oncologia Pediatrica) trial LH2004 for paediatric HL, we identified 769 consecutive patients treated with curative intent from 1st June 2004 to 1st April 2014 with ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine), or hybrid COPP/ABV (cyclophosphamide, vincristine, prednisone, pr…

MaleOncologyCancer ResearchPathologyTime FactorsDatabases Factualmedicine.medical_treatmenthodgkin lymphoma; paediatric; prognostic factorHodgkin lymphoma; Paediatric; Prognostic factor; Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Biomarkers Tumor; Child; Child Preschool; Databases Factual; Disease Progression; Disease-Free Survival; Female; Ferritins; Hodgkin Disease; Humans; Infant; Infant Newborn; Italy; Kaplan-Meier Estimate; Leukocyte Count; Male; Multivariate Analysis; Neoplasm Staging; Platelet Count; Predictive Value of Tests; Proportional Hazards Models; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome; Blood Platelets; EosinophilsKaplan-Meier EstimateProcarbazineLeukocyte Countchemistry.chemical_compound0302 clinical medicineRisk FactorsPrednisoneAntineoplastic Combined Chemotherapy ProtocolsChildPrognostic factorTumorAge FactorsHodgkin DiseaseVinblastineTreatment OutcomeSettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICAItalyOncologyPaediatricChild Preschool030220 oncology & carcinogenesisDisease ProgressionFemalemedicine.drugBlood Plateletsmedicine.medical_specialtyVincristineAdolescentDacarbazineBleomycinDisease-Free SurvivalDatabases03 medical and health sciencesPredictive Value of TestsInternal medicineBiomarkers TumormedicineHumansPreschoolFactualNeoplasm StagingProportional Hazards ModelsRetrospective StudiesChemotherapyPlatelet Countbusiness.industryInfant NewbornInfantNewbornEosinophilschemistryABVDFerritinsMultivariate AnalysisbusinessBiomarkersHodgkin lymphoma030215 immunologyEuropean Journal of Cancer
researchProduct

Estimated Glomerular Filtration Rate Is an Easy Predictor of Venous Thromboembolism in Cancer Patients Undergoing Platinum-Based Chemotherapy

2014

Abstract Background. Reduced estimated glomerular filtration rate (eGFR) has been associated with increased venous thromboembolism (VTE) risk in the general population. VTE incidence significantly increases in cancer patients, especially those undergoing chemotherapy. Despite the evidence that a substantial number of cancer patients have unrecognized renal impairment, as indicated by reduced eGFR in the presence of serum creatinine levels within the reference value, chemotherapy dosage is routinely adjusted for serum creatinine values. Among chemotherapies, platinum-based regimens are associated with the highest rates of VTE. A cohort study was designed to assess the value of pretreatment e…

MaleOncologyCancer ResearchSettore MED/06 - Oncologia Medicamedicine.medical_treatmentPlatinum CompoundsPlatinum-based chemotherapy; Renal impairment; Risk prediction; Risk stratification; Toxicity; Venous thromboembolism; Adult; Aged; Aged 80 and over; Antineoplastic Agents; Cohort Studies; Creatinine; Female; Glomerular Filtration Rate; Humans; Kidney; Male; Middle Aged; Neoplasms; Platinum Compounds; Venous Thromboembolism; Young Adult; Cancer Research; Oncology; Medicine (all)Platinum CompoundKidneyAntineoplastic AgentCohort Studieschemistry.chemical_compoundNeoplasmsRenal impairmentPlatinum-based chemotherapyAged 80 and overeducation.field_of_studyMedicine (all)Hazard ratioVenous ThromboembolismMiddle AgedRisk predictionOncologySymptom Management and Supportive CareCreatinineCohortFemaleHumanGlomerular Filtration RateCohort studyAdultmedicine.medical_specialtyPopulationRenal functionAntineoplastic AgentsYoung AdultInternal medicinemedicineHumanscardiovascular diseaseseducationRisk stratificationAgedChemotherapyCreatinineToxicitybusiness.industryCancerRenal impairment; Risk stratification; Venous thromboembolism; Risk prediction; Toxicity; Platinum-based chemotherapymedicine.diseaseSurgerychemistryNeoplasmCohort StudiebusinessThe Oncologist
researchProduct

Baseline Characteristics Predicting Very Good Outcome of Allogeneic Hematopoietic Cell Transplantation in Young Patients With High Cytogenetic Risk C…

2017

Patients with chronic lymphocytic leukemia with del(17p) or del(11q) have poor long-term prognosis with targeted therapies. Conversely, this retrospective European Society for Blood and Marrow Transplantation registry study shows that young high cytogenetic risk responsive patients with human leukocyte antigen-matched donors have a high 8-year progression-free survival and low 2-year non-relapse mortality after allogeneic stem cell transplantation. This treatment then may compare favorably with targeted therapies for younger high cytogenetic risk patients.Background: Patients with genetically high-risk relapsed/refractory chronic lymphocytic leukemia have shorter median progression-free sur…

MaleOncologyCancer ResearchTransplantation ConditioningBLOODCancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2]medicine.medical_treatmentChronic lymphocytic leukemiaMedizinMULTICENTERKaplan-Meier EstimateHematopoietic stem cell transplantationTHERAPYchemistry.chemical_compound0302 clinical medicineHLA AntigensRisk FactorsIBRUTINIBeducation.field_of_studyHazard ratioHematopoietic Stem Cell TransplantationHematologyMiddle AgedPrognosisRELAPSED CLLTissue DonorsEUROPEAN-SOCIETY3. Good healthRisk factor analysisTreatment OutcomeOncology030220 oncology & carcinogenesisIbrutinibSURVIVALFemaleRefractory Chronic Lymphocytic LeukemiaAdultmedicine.medical_specialty3122 CancersPopulationHLA-matched donorMARROW TRANSPLANTATION03 medical and health sciencesAll institutes and research themes of the Radboud University Medical CenterNon-relapse mortalityInternal medicinemedicineHumansTransplantation HomologouseducationAgedRetrospective StudiesChromosome Aberrationsbusiness.industryKinase- and BCL2 inhibitor refractorymedicine.diseaseLeukemia Lymphocytic Chronic B-CellConfidence intervalSurgeryTransplantationchemistryMATCHED UNRELATED DONORdel(17p)FOLLOW-UPbusiness030215 immunology
researchProduct